Zymeworks Inc. (ZYME) Insider Trading -- Recent Executive & Director Transactions
9 insiders reported 33 Form 4 transactions for Zymeworks Inc. (ZYME) over the past 18 months (most recent 2026-10-09). Recent activity: Schayowitz Adam (EVP, Head of R&D) Buy 37,037 shares, Schayowitz Adam (EVP, Head of R&D) Sell 13,832 shares, Hollywood Mark (EVP & Chief Operating Officer) Buy 939 shares, Hollywood Mark (EVP & Chief Operating Officer) Buy 17,666 shares, Hollywood Mark (EVP & Chief Operating Officer) Sell 6,120 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | Schayowitz Adam | EVP, Head of R&D | Buy | 37,037 | $0 |
| 2026-10-09 | Schayowitz Adam | EVP, Head of R&D | Sell | 13,832 | $357,557 |
| 2026-07-06 | Hollywood Mark | EVP & Chief Operating Officer | Buy | 939 | $20,865 |
| 2026-01-13 | Hollywood Mark | EVP & Chief Operating Officer | Buy | 17,666 | $0 |
| 2026-01-13 | Hollywood Mark | EVP & Chief Operating Officer | Sell | 6,120 | $138,740 |
| 2026-01-12 | Moore Paul Andrew | Chief Scientific Officer | Buy | 17,666 | $0 |
| 2026-01-12 | Moore Paul Andrew | Chief Scientific Officer | Sell | 9,560 | $216,725 |
| 2026-01-12 | Galbraith Kenneth | Chair & CEO | Buy | 64,000 | $0 |
| 2026-01-12 | Galbraith Kenneth | Chair & CEO | Sell | 30,424 | $689,712 |
| 2026-01-12 | Smith Jeffrey T L | EVP & Chief Medical Officer | Buy | 17,666 | $0 |
| 2026-01-12 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 9,310 | $211,058 |
| 2026-01-07 | PATTERSON LEONE D | EVP, Chief Bus & Fin Officer | Buy | 459 | $4,842 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Sell | 22,657 | $568,691 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Buy | 66,666 | $0 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Sell | 31,686 | $795,319 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Buy | 17,168 | $0 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Sell | 9,289 | $233,154 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Buy | 20,000 | $0 |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Sell | 10,821 | $271,607 |
| 2026-01-05 | Smith Jeffrey T L | EVP & Chief Medical Officer | Buy | 20,000 | $0 |
| 2026-01-05 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 10,538 | $264,504 |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Buy | 47,668 | $0 |
| 2025-12-22 | Galbraith Kenneth | Chair & CEO | Buy | 100,000 | $0 |
| 2025-12-22 | Galbraith Kenneth | Chair & CEO | Sell | 47,528 | $1.3M |
| 2025-08-12 | Ciongoli Gregory Austin | Director | Buy | 415,000 | $5.0M |
Source: SEC Form 4 filings · as of 2026-10-09